Zeltiq Aesthetics Inc (ZLTQ) : Deerfield Management Co scooped up 192,583 additional shares in Zeltiq Aesthetics Inc during the most recent quarter end , the firm said in a disclosure report filed with the SEC on Aug 15, 2016. The investment management firm now holds a total of 1,297,000 shares of Zeltiq Aesthetics Inc which is valued at $49,078,480.Zeltiq Aesthetics Inc makes up approximately 2.14% of Deerfield Management Co’s portfolio.
Other Hedge Funds, Including , Everpoint Asset Management sold out all of its stake in ZLTQ during the most recent quarter. The investment firm sold 75,000 shares of ZLTQ which is valued $2,838,000.Columbia Wanger Asset Management reduced its stake in ZLTQ by selling 193,043 shares or 26.58% in the most recent quarter. The Hedge Fund company now holds 533,203 shares of ZLTQ which is valued at $20,176,402. Zeltiq Aesthetics Inc makes up approx 0.22% of Columbia Wanger Asset Management’s portfolio. Croft-leominster Inc sold out all of its stake in ZLTQ during the most recent quarter. The investment firm sold 8,000 shares of ZLTQ which is valued $302,720.Gsa Capital Partners Llp boosted its stake in ZLTQ in the latest quarter, The investment management firm added 54,406 additional shares and now holds a total of 103,101 shares of Zeltiq Aesthetics Inc which is valued at $3,617,814. Zeltiq Aesthetics Inc makes up approx 0.19% of Gsa Capital Partners Llp’s portfolio.
Zeltiq Aesthetics Inc opened for trading at $38 and hit $38.33 on the upside on Thursday, eventually ending the session at $38.21, with a gain of 0.24% or 0.09 points. The heightened volatility saw the trading volume jump to 3,50,834 shares. Company has a market cap of $1,514 M.
On the company’s financial health, Zeltiq Aesthetics Inc reported $-0.12 EPS for the quarter, missing the analyst consensus estimate by $ -0.08 based on the information available during the earnings call on Aug 8, 2016. Analyst had a consensus of $-0.04. The company had revenue of $89.50 million for the quarter, compared to analysts expectations of $79.68 million. The company’s revenue was up 38.9% compared to the same quarter last year. During the same quarter in the previous year, the company posted $0.03 EPS.
Many Wall Street Analysts have commented on Zeltiq Aesthetics Inc. Company shares were Reiterated by Maxim Group on Aug 9, 2016 to “Buy”, Firm has raised the Price Target to $ 48 from a previous price target of $40 .
ZELTIQ Aesthetics Inc. is a medical technology company. The Company is focused on developing and commercializing products utilizing its controlled-cooling technology platform. Its commercial product the CoolSculpting System is designed to reduce stubborn fat bulges. The Company sells its CoolSculpting system to dermatologists plastic surgeons and aesthetic specialists and generates revenue from sales of its CoolSculpting system and from sales of consumables to its customers. Consumables are the CoolSculpting procedure packs that it sells which are needed to perform procedures using its CoolSculpting system. As of December 31 2014 it had an installed base of 3176 CoolSculpting systems installed across approximately 2688 practices across the world. As of December 31 2014 1.5 million CoolSculpting cycles had been shipped to its customers and distributors.